Evidence map›Paper›PMID 22619548›Full record

ArticleInternational journal of nanomedicine2012

Towards development of novel immunization strategies against leishmaniasis using PLGA nanoparticles loaded with kinetoplastid membrane protein-11.

Diego M Santos, Marcia W Carneiro, Tatiana R de Moura, Kiyoshi Fukutani, Jorge Clarencio, Manuel Soto, Socorro Espuelas, Claudia Brodskyn, Aldina Barral, Manoel Barral-Netto and 1 more

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in International journal of nanomedicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Review
  3. Emerging therapeutic targets for treatment of leishmaniasis.Expert opinion on therapeutic targets · 2018
    Review
  4. A Poly(Lactic-Frontiers in immunology · 2017
    Article
  5. Article
  6. Peptide/protein vaccine delivery system based on PLGA particles.Human vaccines & immunotherapeutics · 2016
    Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Diego M SantosCentro de Pesquisas Gonçalo Moniz, FIOCRUZ, Salvador, BA, Brazil.
Marcia W Carneiro
Tatiana R de Moura
Kiyoshi Fukutani
Jorge Clarencio
Manuel Soto
Socorro Espuelas
Claudia Brodskyn
Aldina Barral
Manoel Barral-Netto
Camila I de Oliveira
Fundação Oswaldo Cruz · BRCentro de Biología Molecular Severo Ochoa · ESUniversidad de Navarra · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVaccine development has been a priority in the fight against leishmaniases, which are vector-borne diseases caused by Leishmania protozoa. Among the different immunization strategies employed to date is inoculation of plasmid DNA coding for parasite antigens, which has a demonstrated ability to induce humoral and cellular immune responses. In this sense, inoculation of plasmid DNA encoding Leishmania kinetoplasmid membrane protein-11 (KMP-11) was able to confer protection against visceral leishmaniasis. However, recently the use of antigen delivery systems such as poly(lactic-co-glycolic acid) (PLGA) nanoparticles has also proven effective for eliciting protective immune responses.

methodsIn the present work, we tested two immunization strategies with the goal of obtaining protection, in terms of lesion development and parasite load, against cutaneous leishmaniasis caused by L. braziliensis. One strategy involved immunization with plasmid DNA encoding L. infantum chagasi KMP-11. Alternatively, mice were primed with PLGA nanoparticles loaded with the recombinant plasmid DNA and boosted using PLGA nanoparticles loaded with recombinant KMP-11.

resultsBoth immunization strategies elicited detectable cellular immune responses with the presence of both proinflammatory and anti-inflammatory cytokines; mice receiving the recombinant PLGA nanoparticle formulations also demonstrated anti-KMP-11 IgG1 and IgG2a. Mice were then challenged with L. braziliensis, in the presence of sand fly saliva. Lesion development was not inhibited following either immunization strategy. However, immunization with PLGA nanoparticles resulted in a more prominent reduction in parasite load at the infection site when compared with immunization using plasmid DNA alone. This effect was associated with a local increase in interferon-gamma and in tumor necrosis factor-alpha. Both immunization strategies also resulted in a lower parasite load in the draining lymph nodes, albeit not significantly.

conclusionOur results encourage the pursuit of immunization strategies employing nanobased delivery systems for vaccine development against cutaneous leishmaniasis caused by L. braziliensis infection.

Indexed as

AnimalsAntibodies, ProtozoanAntigens, ProtozoanCytokinesDrug Delivery SystemsFemaleImmunity, CellularLactic AcidLeishmania braziliensisLeishmaniasis, CutaneousLeishmaniasis VaccinesMiceMice, Inbred BALB CNanomedicineNanoparticlesPlasmidsAntibodies, ProtozoanAntigens, ProtozoanCytokinesLactic AcidLeishmaniasis VaccinesPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerProtozoan ProteinsRecombinant ProteinsVaccines, DNAkinetoplastid membrane protein-11Leishmaniananoparticlevaccine

Identifiers

PMID22619548
PMCPMC3356203
OpenAlexW2099293077

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.